According to the latest study from BCC Research, "The Global Influenza Market" is expected to grow from $9.0 billion in 2024 ...

According to DelveInsight's analysis, the market for facioscapulohumeral muscular dystrophy is anticipated to increase during the forecast period (2025-2034), owing to improved diagnosis, treatment ...

Photo: rachel wisniewski/Reuters AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer.

With expansion plans underway, Disney said that the Monsters, Inc. Mike & Sulley to the Rescue! ride at Disney's California Adventure will close in early 2026.

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2.

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more.

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

When Merck & Co. and Daiichi Sankyo last year received an FDA complete response letter for their HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan, the companies hoped to address ...

Daiichi Sankyo and Merck have voluntarily withdrawn the Biologics License Application (BLA) for patritumab deruxtecan, an investigational human epidermal growth factor receptor 3 (HER3)-directed ...

Daiichi Sankyo will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program ...